Stem Cell Clinic

California ballot initiative campaigns are in the final weeks of their signature drives and face the effects of coronavirus – The Center Square

By Stell Cell Research

(The Center Square) California is under a shelter-in-place order due to the coronavirus pandemic, but several ballot initiative campaigns are in the final days or weeks of their signature drives. As of March 23, four citizen-initiated measures have qualified to appear on the ballot in November. An additional nine ballot initiatives could receive enough signatures to appear on the ballot.

The deadline for signature verification is June 25, 2020. However, the process of verifying signatures can take multiple months. Secretary of State Alex Padilla (D) recommends that campaigns file signatures no later than April 21. Campaigns that file signatures after the deadline can still have their proposals appear on the ballot for November 8, 2022.

Gov. Gavin Newsom (D) has directed residents to remain at home, except as needed for food, medicine, and other services deemed essential, due to the pandemic. The California Department of Health has advised that non-essential gatherings be postponed or canceled, and the CDC is recommending that people maintain distance between each other.

Jamie Court, president of Consumer Watchdog, stated, We were getting 70,000 signatures a week until a couple of weeks ago, when it almost stopped. According to Fred Kimball, owner of the signature-gathering firm Kimball Petition Management, Were all flying by the seat of our pants. No one has ever seen this.

Campaigns behind the following nine citizen-initiated measures are seeking a place for their proposals on the general election ballot. Coronavirus, however, could have the effect of limiting the number of signatures that an individual petitioner can collect, especially for campaigns that didnt launch until January 2020.

Property Tax Transfers and Exemptions Initiative (#19-0003): The campaign Homeownership for Families and Tax Savings for Seniors filed 1.43 million signatures on March 4. At least 997,139 signatures need to be valid. The ballot measure would change how tax assessments are transferred between properties for eligible homebuyers and address resetting tax assessments to fair market value on inherited properties and when corporations and other entities acquire control of properties. Homeownership for Families and Tax Savings for Seniors, which is associated with the California Association of Realtors, has raised $12.08 million.

Tax on Commercial and Industrial Properties for Education and Local Government Funding Initiative (#19-0008): An earlier version of the citizen-initiated measure has qualified for the ballot, but the campaign Schools and Communities First is seeking to replace the initiative with an amended version. The campaign needs to file at least 997,139 valid signatures. Schools and Communities First has raised $17.13 million. Both versions of the ballot initiative would amend the state constitution to require commercial and industrial properties, except those zoned as commercial agriculture, to be taxed based on their market value.

Consumer Personal Information Law and Agency Initiative (#19-0021): The ballot initiative seeks to expand the provisions of the California Consumer Privacy Act (CCPA), which was passed in 2018. The campaign Californians for Consumer Privacy raised $3.42 million for this years effort. Robin Swanson, a consultant for the campaign, said, Were in pretty good shape with the numbers that we have, but are adhering to public health requirements and putting public safety first. Like most ballot measure campaigns out there, wed always love more signatures, but were dealing with a stark new reality while the state is on lockdown. At least 623,212 valid signatures need to be filed for the ballot measure.

Stem Cell Research Institute Bond Initiative (#19-0022): Californians for Stem Cell Research, Treatments, and Cures is backing a ballot initiative to issue $5.5 billion in general obligation bonds for the state's stem cell research institute. Spokesperson Sarah Melbostad said the campaigns signature drive has been suspended due to the coronavirus pandemic. "In keeping with the governors statewide order for non-essential businesses to close and residents to remain at home, weve suspended all signature gathering for the time being. ... Were confident that we still have time to qualify and plan to proceed accordingly, said Melbostad. Proponents have raised $5.28 million. The campaign needs to collect at least 623,212 valid signatures.

Dialysis Clinic Requirements and Consent to Close Initiative (#19-0025): Californians for Kidney Dialysis Patient Protection, which backed a defeated dialysis-related initiative in 2018, has raised $5.38 million for the new effort. The campaign needs at least 623,212 valid signatures.

App-Based Drivers Regulations Initiative (#19-0026): With $110.58 million, Protect App-Based Drivers and Services has collected over 1 million signatures, of which 623,212 need to be valid. The campaign has the support of Uber, Lyft, Doordash, Instacart, and Postmates. The ballot measure would consider app-based drivers to be independent contractors and enact several wage and labor policies that would affect app-based drivers and companies. Spokesperson Stacy Wells said, We were really lucky. We got our signatures in fast and were able to get off the streets in seven weeks.

Packaging Waste Reduction Regulations Initiative (#19-0028): The ballot measure would require CalRecycle, in consultation with other agencies, to adopt regulations that reduce the use of product packaging, single-use packaging, and single-use dishes and utensils. The campaign Clean Coasts, Clean Water, Clean Streets has raised $3.26 million. At least 623,212 valid signatures need to be collected.

Legalize Sports Betting on American Indian Lands Initiative (#19-0029): The Coalition to Authorize Regulated Sports Wagering, with the support of several tribal governments, has raised $7.5 million for a ballot measure to legalize sports betting at American Indian gaming casinos and licensed racetracks. The effort to collect 997,139 valid signatures began on January 21, 2020. We are at nearly 1 million signatures and were on a trajectory to reach our goal well ahead of the deadline before the unprecedented orders around COVID-19, said Jacob Mejia, a spokesperson for the campaign. He added, The health and well-being of Californians is foremost. Thus, paid signature-gathering efforts have paused for the time being.

Read the original:
California ballot initiative campaigns are in the final weeks of their signature drives and face the effects of coronavirus - The Center Square

Dad told he has months left to live after stem cell transplant fails – Wales Online

By Stell Cell Research

When Phil Huntley started experiencing cold and flu-like symptoms just weeks after his wedding, he initially thought very little of it.

But after visiting his GP and seeing an out-of-hours doctor, his condition deteriorated to such an extent that he collapsed at home.

Tests in hospital confirmed that not only did the 38-year-old have pneumonia and sepsis, but also a rare form of leukaemia which has now spread to his skin and central nervous system.

He has now been told he may have just months left to live after a stem cell transplant failed.

The most recent news has devastated us, but we remain hopeful that against all odds all will be well, said his wife Sian Huntley, 50.

We are determined to live our best lives, make every day count and be grateful for everything.

We are doing our best to make sure the absolute fear that we feel doesn't take over, and instead we breathe and live each moment with joy and gratitude.

Phil, who married Sian in December 2018, said he started suffering with severe night sweats in January 2019 before he became increasingly unwell.

I was dosing myself up on flu relief and still going to work every day. I carried on like that for a few weeks, recalled Phil, a former employee with the National Trust.

Eventually I went to my GP as I knew something wasn't right, but they just said 'something was going around' at the moment and told me to come back in a few days for a blood test if things didn't improve.

After seeing an out-of-hours GP who gave him antibiotics for a suspected chest infection, his condition deteriorated further.

One day it took until 2pm to get out of bed. I managed to find the strength to have a shower. At one point I lost my footing, but moments later everything just went black.

I woke up in Sian's arms who was on the phone to the ambulance.

In A&E at Withybush Hospital in Haverfordwest, blood tests revealed that Phil had pneumonia and sepsis, a condition which causes the body's immune to go into overdrive and start attacking healthy tissue and organs.

It was also discovered that the Solva resident had leukaemia and would need to be transferred to the University Hospital of Wales (UHW) in Cardiff.

Leukaemia was the last thing that crossed my mind, said Phil.

I think the gravity of the whole situation only hit me towards the end of my ambulance ride between Withybush and UHW.

I just felt shock - and such disbelief that I could have laughed. Between myself and Sian we have four children and all I could do is think of them.

While Phil recovered quickly from sepsis, he would need many gruelling rounds of chemotherapy to treat the leukaemia.

I was in UHW for two months to begin with, a week of which was in intensive care, Phil added.

That's all pretty much a blur, and for the first month I didn't leave my bed.

In the second month I had to learn to walk again. When I managed to get myself to the toilet for the first time on my own it was a little personal victory.

Sian added that their four children Dylan, nine; Ben, 10; Katie, 14; and Amy, 16, have all been brilliant while Phil has been unwell.

She said: They all help in any way they can. We know they are struggling and worrying about things. The two older girls have taken on some additional responsibility such as looking after Ben.

But emotionally it has really taken its toll.

Phil, who was later also found to have aspergillosis, a condition which causes major breathing problems, ended up contracting sepsis four times in total following every round of chemotherapy.

Every time he had chemotherapy we were on red alert and would need to take him to hospital, said Sian.

But the staff at Withybush Hospital were amazing and acted straight away to prevent Phil from going into septic shock.

Video Unavailable

Click to playTap to play

Play now

In November 2019, nurses informed Phil that a positive stem cell match had been found for him, giving him hope that he may be cured.

It was a 27-year-old guy from somewhere in Wales and the match was 100%, he said.

But by this point I'd developed leukaemia of the skin, which is only found in around 2% of leukaemia patients. The Cardiff team hadn't really dealt with it previously.

I was in isolation for four to six weeks in UHW for chemotherapy, then I went to Velindre for radiotherapy on my skin, and then I went back to UHW for the transplant to be carried out which was done through an IV drip into my arm.

While Phil started to see signs of improvement early on after the transplant, by mid February 2020 the legions that had vanished from his skin began to reappear.

It's been horrendous, said Sian. At times none of this has seemed real.

His condition is so rare that there is currently no research or medical trials taking place.

A GoFundMe page was set up for the family by close friend Jacqueline Roberts so they can enjoy the time they have left together by going on regular trips around Wales and the UK.

To donate, go to https://www.gofundme.com/f/phil-the-super-hero

But sadly, due to the outbreak of coronavirus and Phil being classified as an extremely at risk patient, he is unable to leave his Pembrokeshire home for at least the next three months.

Sian admitted that she was terrified of picking up the virus and passing it onto her severely unwell husband.

Sian said: We wanted to make some memories as a family, but we are obviously very mindful of the current situation.

We wanted to go to Cornwall as a family but that's obviously not happening now. We are very fortunate to live in a very beautiful part of Wales anyway.

Phil, who is now having monthly injections to slow down the progress of the leukaemia, said he is looking forward to spending some time at home with his family.

I've been either in the hospital or stuck in the house for quite some time now. I just feel sorry for the children as they cannot go anywhere, he said.

Link:
Dad told he has months left to live after stem cell transplant fails - Wales Online

The Global Cell Expansion Market is expected to grow from USD 11,923.12 Million in 2018 to USD 30,023.12 Million by the end of 2025 at a Compound…

By Stell Cell Research

The positioning of the Global Cell Expansion Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

New York, March 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Expansion Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05872140/?utm_source=GNW

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Expansion Market including are Beckman Coulter Inc., Becton, Dickinson and Company, Merck KGaA, Terumo BCT, Thermo Fisher Scientific, Inc., Corning Incorporated, GE Healthcare, Lonza Group LTD., Miltenyi Biotec, Promocell GmbH, Sartorius AG, Stemcell Technologies, Inc., and Takara Bio Inc..

On the basis of Product, the Global Cell Expansion Market is studied across Consumables and Instruments.

On the basis of Cell Type, the Global Cell Expansion Market is studied across Animal Cells and Human Cells.

On the basis of Application, the Global Cell Expansion Market is studied across Cancer and Cell-Based Research and Regenerative Medicine and Stem Cell Research.

On the basis of End User, the Global Cell Expansion Market is studied across Biotechnology & Biopharmaceutical Companies, Cell Banks, and Research Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Cell Expansion Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Cell Expansion Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Cell Expansion Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Cell Expansion Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Cell Expansion Market

The report answers questions such as:1. What is the market size of Cell Expansion market in the Global?2. What are the factors that affect the growth in the Global Cell Expansion Market over the forecast period?3. What is the competitive position in the Global Cell Expansion Market?4. Which are the best product areas to be invested in over the forecast period in the Global Cell Expansion Market?5. What are the opportunities in the Global Cell Expansion Market?6. What are the modes of entering the Global Cell Expansion Market?Read the full report: https://www.reportlinker.com/p05872140/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Go here to read the rest:
The Global Cell Expansion Market is expected to grow from USD 11,923.12 Million in 2018 to USD 30,023.12 Million by the end of 2025 at a Compound...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research Key Players, Industry Overview and Forecasts to 2027 – Packaging News 24

By Stell Cell Research

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis to 2027 is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of Autologous Stem Cell and Non-Stem Cell Based Therapies market with detailed market segmentation by application, end user, and geography. The global Autologous Stem Cell and Non-Stem Cell Based Therapies market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Autologous Stem Cell and Non-Stem Cell Based Therapies market players and offers key trends and opportunities in the market.

Get sample PDF copy @https://www.theinsightpartners.com/sample/TIPRE00006725/

The key players influencing the market are:

This report contains:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market report also provide a in-depth understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, and opportunities in the market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of last three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garner Autologous Stem Cell and Non-Stem Cell Based Therapies Market revenue by understanding the strategic growth approaches.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market is a combination of qualitative as well as quantitative analysis which can be broken down into 40% and 60% respectively. Market estimation and forecasts are presented in the report for the overall global market from 2020 2027, considering 2020 as the base year and 2020 2027 forecast period. Global estimation is further broken down by segments and geographies such as North America, Europe, Asia-Pacific, Middle East & Africa and South America covering major 16 countries across the mentioned regions. The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market.

Report Spotlights

Purchase This Report @https://www.theinsightpartners.com/buy/TIPRE00006725/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876Email: [emailprotected]

See more here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research Key Players, Industry Overview and Forecasts to 2027 - Packaging News 24

Global Cell Culture Market Industry Analysis and Forecast (2019-2026) – Stock Market Herald

By Stell Cell Research

Global Cell Culture Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 12% during forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/33004/

Utilization of cell cultures has improved to an extent where old small-scale production and handling of cultures decreasing for the growing demand. This has stimulated the development of automatic large-scale cell culture systems which are proficient of creating high throughput cell cultures of exceptional purity and in larger quantities. Continued development of cell culture methods and applications has poised this market to anticipate a steady and substantial growth by to 2026.

Because of the revolutions in genetic engineering there has been a major increase in the usage of protein based biopharmaceuticals. Their invention is greatly dependent on the protein expression systems resultant from mammalian cell cultures and production of high yielding cell lines. This newly developed application of cell cultures in the biopharmaceutical is responsible for most of the revenue generated from this segment and is also estimated to be the main cause for the same during the forecast period.

Largest share of revenue produced worldwide was accounted for by North America in 2017. Because of the introduction and progress of automated cell culture techniques and increasing usage of stem cell therapy in the region, cell culture finds maximum application in U.S. and Canadian life science laboratories. In U.S. alone, cell culture mechanization for cell-based assays like induced pluripotent stem cell research, cellular expression, culturing of monoclonal antibodies (MaBs) and cryobanking accounted for around a third of the income generated.

As a result of unconventional developments in bioreactors, companies are also contained in the summary and improvement of 3D cell culture methods which are a step up from the predictable 2D cell cultures. Three-dimensional cell collections which are acquired from 3D cultures are more accurate models of in vivo cells and it is projected that there expansion will further boost the market growth.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/33004/

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Cell Culture Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in Cell Culture Market.Scope of Global Cell Culture Market:

Global Cell Culture Market by Product:

Consumables EquipmentGlobal Cell Culture Market by Application:

Stem Cell Vaccines Therapeutic proteinsGlobal Cell Culture Market by End User:

Pharma Research InstitutesGlobal Cell Culture Market by Region:

North America Asia Pacific Europe Middle East & Africa South AfricaKey Players Operating in the market includes:

Becton Dickinson and Company Thermo Fisher Scientific Merck KGaA HiMedia Laboratories GE Healthcare Lonza Corning Incorporated Sartorius AG Eppendorf AG PromoCell GmbH Danaher Corporation Irvine Scientific InvivoGen CellGenix GmbH

MAJOR TOC OF THE REPORT

Chapter One: Cell Culture Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Culture Market Competition, by Players

Chapter Four: Global Cell Culture Market Size by Regions

Chapter Five: North America Cell Culture Revenue by Countries

Chapter Six: Europe Cell Culture Revenue by Countries

Chapter Seven: Asia-Pacific Cell Culture Revenue by Countries

Chapter Eight: South America Cell Culture Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Culture by Countries

Chapter Ten: Global Cell Culture Market Segment by Type

Chapter Eleven: Global Cell Culture Market Segment by Application

Chapter Twelve: Global Cell Culture Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Culture Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-culture-market/33004/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Read the original:
Global Cell Culture Market Industry Analysis and Forecast (2019-2026) - Stock Market Herald

Scientists ‘Reset’ The Age of Stem Cells From a Supercentenarian Who Lived to 114 – ScienceAlert

By Somatic Stem Cells

For the first time, scientists have reprogrammed the stem cells of a 114-year-old woman, the oldest donor to date.

After first transforming cells from her blood sample into induced pluripotent stem cells (iPSCs), the researchers then generated mesenchymal stem cells, which help to maintain and repair tissues like bone, cartilage and fat.

"We set out to answer a big question: Can you reprogram cells this old?" says stem cell biologist Evan Snyder at Sanford Burnham Prebys Medical Discovery Institute in California.

"Now we have shown it can be done, and we have a valuable tool for finding the genes and other factors that slow down the aging process."

Stem cells are sometimes called "cellular Rosetta stones", because they allow us to study disease, cancer, ageing and regeneration like never before.

The most valuable type are embryonic stem cells (ESCs), but their acquisition is linked to some ethical issues, and such cells can be difficult to get a hold of. Thankfully, somatic cells, or adult stem cells, can be found in any human; we have the technology to genetically reprogram these units into induced pluripotent stem cells, which are nearly as potent as ESCs.

Until now, however, we weren't sure just how long an adult's cells remain programmable in this way. While some previous research suggests older stem cells cannot be reprogrammed, in recent years, scientists have been able to generate iPSCs from centenarians, or people who live to be more than 100 years old.

So, what about those who've won an even bigger genetic lottery? What about supercentenarians?

In the whole wide world, currently we know of only 28 people verified to be over the age of 110. This unique population is difficult to study, not only because of its limited sample size but also because of our records, which can be pretty shoddy at times.

Nevertheless, research so far has found supercentenarians not only age slower, they also show a strange immunity in general to chronic age-related diseases, like Alzheimer's and Parkinson's, that doesn't seem to have a lot to do with lifestyle.

"Why do supercentenarians age so slowly?" says Snyder. "We are now set to answer that question in a way no one has been able to before."

To do this, the team reprogrammed lymphoblastsfrom three donors: the supercentenarian woman, a healthy 43-year-old individual, and an 8-year-old child with a condition that causes rapid ageing.

Not only did the supercentenarian cells transform into iPSCs just as easily as the others, the telomeres - sequences of 'protective' DNA that sit at the ends of our chromosomes and shrink as we age - were also reset to more "youthful levels".

Granted, this telomere resetting didn't occur as frequently in older cells, only a third of the time. Nevertheless, the authors say what they were able to achieve on these occasions was equivalent to turning back the cellular clock from age 114 to age zero.

"These data indicate that extreme age is not an absolute barrier to reprogramming with restoration of telomere length," the authors write.

What's more, their technique only required four reprogramming factors - a manageable number that will make it relatively easy for scientists to see how these supercentenarian stem cells compare in the long run.

They claim reprogramming donor cells from extremely or prematurely aged donors is feasible, and that by doing so with retrospective samples, we might be able to expand on this small pool of supercentenarian donors.

The authors of the study hope their research will allow us to better investigate how and why supercentenarians live so long and are so extraordinarily resistant to degenerative disease. There's much we can learn from these remarkable people.

The study was published in Biochemical and Biophysical Research Communications.

Visit link:
Scientists 'Reset' The Age of Stem Cells From a Supercentenarian Who Lived to 114 - ScienceAlert

The Global Cell Culture Market is expected to grow from USD 14,923.23 Million in 2018 to USD 35,236.23 Million by the end of 2025 at a Compound Annual…

By Stem Cell Medicine

The positioning of the Global Cell Culture Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

New York, March 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Culture Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05872141/?utm_source=GNW

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Culture Market including are Becton, Dickinson and Company, Cellgenix, Corning, Danaher, Eppendorf, Fujifilm Irvine Scientific, GE Healthcare, Hi-Media Laboratories, Invivogen, Lonza Group AG, Merck KGaA, Miltenyi Biotec, Promocell, and Sartorius AG.

On the basis of Product, the Global Cell Culture Market is studied across Consumables and Equipment.

On the basis of Application , the Global Cell Culture Market is studied across Biopharmaceutical Production, Diagnostics, Drug Screening and Development, Stem Cell Research, and Tissue Engineering & Regenerative Medicine.

On the basis of End User , the Global Cell Culture Market is studied across Cell Banks, Hospitals and Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Research Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Cell Culture Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Cell Culture Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Cell Culture Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Cell Culture Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Cell Culture Market

The report answers questions such as:1. What is the market size of Cell Culture market in the Global?2. What are the factors that affect the growth in the Global Cell Culture Market over the forecast period?3. What is the competitive position in the Global Cell Culture Market?4. Which are the best product areas to be invested in over the forecast period in the Global Cell Culture Market?5. What are the opportunities in the Global Cell Culture Market?6. What are the modes of entering the Global Cell Culture Market?Read the full report: https://www.reportlinker.com/p05872141/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Continue reading here:
The Global Cell Culture Market is expected to grow from USD 14,923.23 Million in 2018 to USD 35,236.23 Million by the end of 2025 at a Compound Annual...

The Global Cell Isolation/Cell Separation Market is expected to grow from USD 5,721.23 Million in 2018 to USD 15,089.25 Million by the end of 2025 at…

By Stem Cell Medicine

New York, March 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Isolation/Cell Separation Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05872137/?utm_source=GNW

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Isolation/Cell Separation Market including are Beckman Coulter Inc. (Subsidiary of Danaher Corporation), Becton, Dickinson and Company, Merck KGaA, Terumo Bct, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Miltenyi Biotec, Pluriselect Life Science Ug (Haftungsbeschrnkt) & Co. Kg, and Stemcell Technologies, Inc..

On the basis of Product, the Global Cell Isolation/Cell Separation Market is studied across Consumables and Instruments.

On the basis of Cell Type, the Global Cell Isolation/Cell Separation Market is studied across Animal Cells and Human Cells.

On the basis of Cell Source, the Global Cell Isolation/Cell Separation Market is studied across Adipose Tissue, Bone Marrow, and Cord Blood/Embryonic Stem Cells.

On the basis of Technique, the Global Cell Isolation/Cell Separation Market is studied across Centrifugation-Based Cell Isolation, Filtration-Based Cell Isolation, and Surface Marker-Based Cell Isolation.

On the basis of Application, the Global Cell Isolation/Cell Separation Market is studied across Biomolecule Isolation, Cancer Research, In Vitro Diagnostics, Stem Cell Research, and Tissue Regeneration & Regenerative Medicine.

On the basis of End User, the Global Cell Isolation/Cell Separation Market is studied across Biotechnology & Biopharmaceutical Companies, Hospitals & Diagnostic Laboratories, and Research Laboratories & Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Cell Isolation/Cell Separation Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Cell Isolation/Cell Separation Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Cell Isolation/Cell Separation Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Cell Isolation/Cell Separation Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Cell Isolation/Cell Separation Market

The report answers questions such as:1. What is the market size of Cell Isolation/Cell Separation market in the Global?2. What are the factors that affect the growth in the Global Cell Isolation/Cell Separation Market over the forecast period?3. What is the competitive position in the Global Cell Isolation/Cell Separation Market?4. Which are the best product areas to be invested in over the forecast period in the Global Cell Isolation/Cell Separation Market?5. What are the opportunities in the Global Cell Isolation/Cell Separation Market?6. What are the modes of entering the Global Cell Isolation/Cell Separation Market?Read the full report: https://www.reportlinker.com/p05872137/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original post:
The Global Cell Isolation/Cell Separation Market is expected to grow from USD 5,721.23 Million in 2018 to USD 15,089.25 Million by the end of 2025 at...

How Crucial is the Cellular Communications Between the Detached Cancerous Cells and Fibroblast for Growing Metastasis – Spark Health MD

By Stem Cell Medicine

Researchers from the German Cancer Research Center and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine have found that some tumor cells get separated from the parent tumors and then stimulate the connective tissue cells to release certain transmitters for promoting metastasis. This process is done to colonize the other organs and the detached tumors manipulate the environment according to their needs for creating the metastatic niche.

This discovery is helpful for scientists to better understand the mechanism that how these harmful metastases arise. This research paper is published in the journal Nature Communications.

When cancer spreads to other parts of the body from the initial site then the process is called metastasis. It usually develops when the cancerous cells break their connection from the main or parent tumor and move to the bloodstream or lymphatic system. Through these systems, the detached tumor travels far away from the main site and form new tumors when they settle down in specific tissue.

If the cancerous cells detached from the parent tumors, then many of them were died before colonizing other tissues and forming metastases. Because When a tumor detached from the parent tumor then the body immunes system gets activated and protects the healthy cells and tissues of the body from the intruding effects of cancerous cells.

These migrant cells will only survive in the body if they have the power to manipulate their new environment for creating the metastatic niche. This metastatic niche makes them survive in the body by protecting against the bodys immune system.

Thordur Oskarssan and his team of researchers from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH) are concerned in exploring the mechanism that how this metastatic niche evolves. Scientists found that in breast cancer some specific aggressive cells stimulate a certain condition which is similar to the inflammation in the lung tissue. So, it confirms that these cells colonize the other healthy tissues and promote metastases.

Also Read: Human Immune System is Effective Against a Number of Viruses

Two inflammatory signaling molecules known as interleukins are released from the detached cancerous cells. In microenvironment, these interleukins stimulate fibroblasts in the lungs to release two more inflammatory signaling molecules i.e. CXCL10 and CXCL9.

Migrant cancer cells carry receptors on their surface that attach to these signaling molecules which is a pivotal step during the process of metastases. The signaling molecules (CXL10 and CXCL9) and inflammation aid the particular aggressive breast cancerous cells to colonize other tissues and form metastases.

Maren Pein who is a lead author of the study said that the same tumors cells that provoke the fibroblast to release CXCL10 and CXCL9 also contain some other receptors for theses cytokines which help the growing process of metastases. This indicates that cellular communication between fibroblasts and detached cancerous cells in the new microenvironment is very crucial for metastasis.

During the experimental studies, scientists treated the lungs of mice with an inhibitor which blocked the receptors on the cancer cells. These inhibitors used to prevent the growing process of metastasis.

Scientists took tissue samples from the patients of breast cancer and found that the same cellular communication was also present in breast cancer cells. The process in which tumors cells having the relevant receptors utilize these interactions along with fibroblast to create the metastatic niche is also found in the breast cancer patients.

Oskarsson further explained that before developing any treatment approaches, it is necessary to understand the exact mechanism of metastasis. Initially, the study was carried out to explore the actual process that helps to arise metastases. A better understanding will enable scientists to develop different ways to prevent metastases in the future.

Read more here:
How Crucial is the Cellular Communications Between the Detached Cancerous Cells and Fibroblast for Growing Metastasis - Spark Health MD

Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position – Seeking Alpha

By Stem Cell Medicine

Introduction

Sangamo Therapeutics (SGMO) is a clinical-stage biotech company focusing on the research and development of genomic medicine across 4 distinct technology platforms: gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation.

Sangamo is best-known for developing its proprietary gene-editing technology, zinc finger proteins ("ZFPs"), which is a naturally occurring class of transcription factor proteins found in humans and other species. The company has used its internal know-how and technical expertise to develop a proprietary synthetic ZFP platform with potential clinical utility in ex vivo gene-edited cell therapy, in vivo genome editing, and in vivo genome regulation.

ZFPs also can be engineered to make zinc finger nucleases ("ZFNs") which proteins that can be used to specifically modify DNA sequences by knocking in or knocking out select genes, or genome editing, and ZFP transcription-factors ("ZFP-TFs") which are proteins that can be used to selectively increase or decrease gene expression.

Sangamo is developing a series of clinical programs, which are either wholly-owned or partnered with well-established pharma and biotech companies, to focus on 3 therapeutics areas in inherited metabolic disease ("IMDs"), central nervous system ("CNS), and inflammatory and autoimmune diseases. Its full list of clinical pipeline programs is listed in Figure 1.

Figure 1 Sangamo Therapeutics' Clinical Pipeline (Source)

The company's most advanced program is an investigational gene therapy for severe hemophilia A, SB-525. SB-525 is developed under a global collaboration with Pfizer (PFE), of which the rights of SB-525 have been transferred to Pfizer to run a phase 3 trial. In December 2019, both companies announced updated initial data from the phase1/2 trial of SB-525. SB-525 was generally well-tolerated and demonstrated a sustained increase in Factor VIII activity. SB-525 has been granted RMAT, Orphan Drug, and Fast Track designation by the FDA as well as Orphan Medicinal Product Designation by the European Medicines Agency ("EMA").

Beyond SB-525, the company is also investigating 2 wholly-owned gene therapy. ST-920 is being evaluated to treat Fabry disease, a rare inherited metabolic disease, in a phase 1 study in the US and UK. SB-920 has received Orphan Drug designation by the FDA. The company also plans to advance ST-101 into clinical trials in 2021 to treat phenylketonuria ("PKU") which is a rare inherited disorder that originates from a defect in the PAH gene and results in a harmful accumulation of phenylalanine in cells throughout the body.

Sangamo is working with Sanofi (NASDAQ:SNY) to develop ex vivo gene-edited cell therapies, ST-400 and BIVV-003, for transfusion-dependent beta-thalassemia ("TDT") and sickle cell disease ("SCD") respectively. Both ST-400 and BIVV-003 are related product candidates using the same technology involving gene editing of a patient's own hematopoietic stem progenitor cells using non-viral delivery of ZFN technology.

Sangamo is the phase 1/2 study of ST-400 in 6 patients with TDT while Sanofi is recruiting the phase1/2 study evaluating BIVV-003 in patients with SCD, and Sanofi is responsible for the subsequent development, manufacturing, and commercialization of both programs.

In Dec 2009, Sangamo presented interim results for the first 3 patients ST-400. As of the data cut date, 2 more patients have been enrolled although they were not included in the interim updates. The 3 patients treated with ST-400 experienced prompt hematopoietic reconstitution, demonstrating neutrophil engraftment in 14-22 days and platelet engraftment in 22-35 days. No emerging clonal hematopoiesis had been observed as measured by on-target indel pattern monitoring in the three treated patients. The downside of the data readout is that its treatment of TDT appears to be not as efficacious as other competitors such as bluebird bio (BLUE).

Sangamo also has a global collaboration and license agreement with Kite Pharma, a wholly-owned subsidiary of Gilead Sciences (GILD), for the development of engineered cell therapies for cancer. The company is working together with Kite to design ZFNs and viral vectors to disrupt and insert select genes in T cells and natural killer cells. The first program of this agreement expected to start a clinical trial in 2020 is KITE-307, which is an allogeneic anti-CD19 CAR-T cell therapy. Given the well-documented struggles of Kite's approved autologous CAR-T, Yescarta, the success of allogeneic CAR-Ts will be very beneficial.

Lastly, Sangamo is also evaluating the potential of regulatory T-cells ("Tregs") genetically modified with a CAR ("CAR-Tregs") in solid organ transplantation. CAR-Treg cell therapies are being conducted in several preclinical studies in autoimmune and inflammatory diseases such as multiple sclerosis ("MS") and inflammatory bowel disease ("IBD"). The most advanced CAR-Treg cell therapy is TX200, which is an autologous treatment for the prevention of solid organ transplant rejection and the clinical trial is expected to be initiated in 2020.

Sangamo is only planning to start a new clinical trial for its in vivo genome editing programs. SB-913 is a second-generation ZFNs program that will be used to treat Mucopolysaccharidosis type II ("MPS II") and a new clinical trial is planned to start this year.

The company had previous programs from first-generation ZFNs that have been halted as they did not demonstrate enough clinical benefits. The company plans to use data from the SB-913 study to definite the next steps for its in vivo genome editing programs.

The company also has several preclinical programs evaluating their ZFP-TF technology as a novel therapeutic approach for CNS diseases. In December, Sangamo announced a collaboration with Biogen (BIIB) to develop and commercialize ST-501 for tauopathies including Alzheimer's disease, ST-502 for synucleinopathies including Parkinson's disease, a third undisclosed neuromuscular disease target, and up to 9 additional neurological disease targets. Under the terms of the agreement, Biogen will pay Sangamo $350M upfront, inclusive of a license fee and equity investment, and Sangamo is eligible to receive up to $2.37B in future milestones.

Sangamo also has a partnership with Pfizer and Takeda (NYSE:TAK) to develop and evaluate ZFP-TFs. The company is working with Pfizer to evaluate ALS and frontotemporal lobar degeneration ("FTLD") that are linked to the mutations in the C9ORF72 gene. In the partnership with Takeda, the company is evaluating a preclinical program for Huntington's disease in which ZFP-TF is designed to differentially down-regulate the mutated disease-causing huntingtin gene ("HTT gene") while preserving the expression of the normal version of the gene.

As of 31 December, 2019, cash and equivalents on hand was $385M. The amount is excluding the $350M injection from the collaboration with Biogen, and when factored in, cash on hand should comfortably be in the range of high $600-700M. This should give them a comfortable runway to fund all operations well into 2021, an important point given that the recent stock market crash which limits any secondary offering options.

Impressively, the company has managed to strike several high-profile partnerships with 5 global biotech/big pharma companies. Such partnerships not only validate Sangamo's technology and capabilities, but they also provide future avenues of funding with as much as $6.34B royalties on net product sales and potential milestone payments due to the company.

Figure 1 Sangamo Therapeutics' Partnerships (Source)

In terms of competition, the company competes with several players, particularly in the cell and gene therapy space. bluebird bio has more advanced programs in both TDT and SCD and, to date, has shown much better efficacy. There are also other companies such as CRISPR Therapeutics (CRSP) that are using an alternative gene-editing method, CRISPR/Cas9 in gene therapy. Other companies such as Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are also developing CRISPR/Cas9 for treatments in TDT and SCD, although it must be noted that these are not their lead programs.

In terms of allogeneic CAR-T, there are more established players such as Allogene Therapeutics (ALLO), Cellectis (CLLS), and Precision Biosciences (DTIL). The main difference among these companies is primarily the choice of gene-editing tools with Allogene and Cellectis using TALEN while Precision is using ARCUS. All these companies are, currently, in a similar stage of clinical development.

In addition to healthy donors derived allogeneic therapies, Fate Therapeutics (FATE) is developing allogeneic therapies from induced pluripotent stem cells ("iPSCs") as a renewable cell source. The advantage of this is that product consistency and potency will be improved, and the manufacturing process will be akin to the well-established biologics where they are produced from a single cell line. It is notable to note that Allogene is also investigating using iPSCs as a renewable cell source. Also, Atara Biotherapeutics (ATRA) is developing an Epstein-Barr Virus ("EBV")-based allogeneic T cell therapy platform. Their lead program is in Phase 3 and a BLA filing is expected by the second half of the year. That should put them in the lead position of commercializing an allogeneic T cell therapy and the company is gradually moving into allogeneic CAR-T space as well.

Sangamo is, currently, trading at a market cap of around $700M, which is almost as much as its cash position. While its cash position will eventually deplete to fund operations and clinical trials, the current valuation means that there is also no value for its technology and intellectual position. I consider it a good time to take up a small position in Sangamo, especially if investors have a time horizon of at least a year to weather the COVID-19 black swan event and wait for further clinical updates from the company.

It must be cautioned though that investing in clinical-stage biotech can be extremely risky, given the binary nature of the field. This is especially so, given the market turmoil from the COVID-19 pandemic. The pandemic has also led to several countries announcing lockdowns, which have disrupted supply chain and operations. Several clinical trials have already been delayed globally and this may impact Sangamo negatively, as their cash burn will continue even if clinical trials are delayed.

Disclosure: I am/we are long ATRA, BLUE. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

See more here:
Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position - Seeking Alpha

→←